北米の黒色腫がん診断市場
Market Size in USD Billion
CAGR :
% 
USD
1,964.80 Million
USD
3,466.02 Million
2022
2030
 予測期間 |
2023 –2030 |
 市場規模（基準年） |
USD 1,964.80 Million |
 Market Size (Forecast Year) |
USD 3,466.02 Million |
 CAGR |
% |
| 主要市場プレーヤー |
北米の黒色腫がん診断市場、製品タイプ別（機器、消耗品および付属品、その他）、検査タイプ別（バイオマーカー検査、画像検査、生検、蛍光in situハイブリダイゼーション（FISH）検査、比較ゲノムハイブリダイゼーション（CGH）検査、免疫組織化学（IHC）検査、その他）、エンドユーザー別（病院、関連研究所、独立診断研究所、診断画像センター、がん研究機関、その他）、流通チャネル別（直接入札および小売販売） - 業界動向および2030年の予測。
北米のメラノーマ癌診断市場の分析と洞察
非侵襲性検査法に対する需要が世界的に高まったことで、市場の需要が高まっています。より良い医療サービスを求める医療費の増加も、市場の成長に貢献しています。主要な市場プレーヤーは、この重要な時期にさまざまな高速診断に重点的に取り組んでいます。さらに、黒色腫がん診断に対する政府の取り組みも、黒色腫がん診断市場の需要増加に貢献しています。
市場プレーヤーによる医療費支出の戦略的取り組みの増加は、市場にチャンスをもたらしています。しかし、新興経済国における熟練した認定専門家の不足と黒色腫がんの診断手順の高コストは、市場の成長に対する主要な課題です。
北米の黒色腫がん診断市場は、2023年から2030年の予測期間に市場成長を遂げると予想されています。データブリッジマーケットリサーチは、市場は2023年から2030年の予測期間に7.4%のCAGRで成長し、2022年の19億6,480万米ドルから2030年には34億6,602万米ドルに達すると分析しています。
|
レポートメトリック |
詳細 |
|
予測期間 |
2023年から2030年 |
|
基準年 |
2022 |
|
歴史的な年 |
2021 (2020-1015 までカスタマイズ可能) |
|
定量単位 |
収益（百万米ドル） |
|
対象セグメント |
製品タイプ別（機器、消耗品、付属品、その他）、検査タイプ別（バイオマーカー検査、画像検査、生検、蛍光in situハイブリダイゼーション（FISH）検査、比較ゲノムハイブリダイゼーション（CGH）検査、免疫組織化学（IHC）検査、その他）、エンドユーザー別（病院、関連ラボ、独立診断ラボ、診断画像センター、がん研究機関、その他）、流通チャネル別（直接入札および小売販売） |
|
対象国 |
米国、カナダ、メキシコ |
|
対象となる市場プレーヤー |
Nanostring、Thermo Fisher Scientific Inc.、Quest Diagnostics Incorporated、Agilent Technologies, Inc、QIAGEN、Inivata Ltd、F. Hoffman-La Roche Ltd、Abbott、AMLo Biosciences Limited、Myriad genetics Genetics Inc、Castle Biosciences、DermTech、Michael Diagnostics Ltd、Damae Medical、Skin Analytics、DermLite、DermaSensor、Skyline Dx、Neracare GmbH、VERISKIN INC.、Illumina Inc、bioMerieux SA など |
市場の定義
メラノーマがんの診断は、皮膚細胞と分子を研究してメラノーマがんを特定するプロセスとして知られています。これらのメラノーマがんの診断は、研究室で行われるさまざまなテストの助けを借りて、特定の細胞または分子を研究、分析、診断するための戦略として使用されます。これは、特定のバイオマーカーの測定や皮膚細胞内のバイオマーカーの特定に特に使用されます。メラノーマがんの診断は、より効率的なテストとより迅速な診断を提供することを目的として使用されます。
黒色腫がんの診断は、医師ががんの段階を見つけ、さまざまな段階の患者を効果的に治療するのに役立ちます。さらに、臨床実践の可能性を秘めており、黒色腫がんの診断の効率を高めるためにいくつかの検査が追加サポートとして使用され、主要な市場プレーヤーの存在も市場の成長に貢献しています。
北米のメラノーマ癌診断市場の動向
ドライバー
-
悪性黒色腫の早期診断の需要が高まる
潜在的に致命的な癌である黒色腫は、皮膚に最も多く見られます。北米規模で黒色腫の発生率は大幅に増加しています。発生率は、肌の色が白い人々と低緯度地域で最も高くなっています。黒色腫は、死亡者あたりの病気による平均寿命が最も長い癌の 1 つです。黒色腫は、発生率と死亡率の上昇により、個人的および経済的に深刻な負担となっています。さまざまな高リスク地域では、さまざまな成功度の予防策が講じられています。病気の発生とリスク要因は、研究イニシアチブを通じてより深く理解する必要があります。
-
予防健康診断の好感度が上昇
予防健康診断は、メラノーマがんの初期発見のために行われる予防措置です。また、予防健康診断の希望が高まることで、将来起こりうるあらゆる病気への感染を防ぐことができます。
検査を促進する意識は、メラノーマがん予防の最も重要な要素です。検査は、がんの特定と、早期段階での損失を抑えるための危険因子の検査で構成されています。
機会
-
メラノーマ癌治療に対する医療費の増加
医療インフラの拡大は市場にとってチャンスです。医療への投資が増えれば、がんに気づき、予防と治療のために自分の健康状態を診断する人が増えるからです。
がん治療のための医療費の増加は、患者が手間をかけずに高度な治療を受け、より良い診断と治療を受けて早期回復するのにも役立ちます。医療費は、自己負担（患者が自分の治療費を支払う）、政府支出、健康保険や非政府組織の活動などの資金源の組み合わせで構成されています。このため、がん治療のための医療費の増加は、市場の需要を伸ばす機会として機能しています。
-
Strategic initiatives by major players
Increasing rates of various types of disease and their severity are widely seen among people globally. The dramatic rise in research quality and increasing research opportunities is because of various strategic initiatives the market players take. They are taking initiatives such as product launch, collaborations, mergers, acquisitions, and many more over the years and is expected to lead and create more opportunities in the market. For instance, Evonik invested in the short-term growth of its specialty melanoma cancer diagnostics production at its Hanau and Dossenheim locations in Germany, which supplied two of the four melanoma cancer diagnostics for the Pfizer/BioNTech vaccine. According to Spencer, the first batches were delivered to BioNTech in April 2021, months ahead of schedule.
Restraints/Challenges
- Strict regulations and standards for the approval and commercialization of melanoma cancer diagnostic products
The stringent regulations for the commercialization of any product in the market are proving to be a big challenge for the manufacturers of cancer diagnostic products globally that have their own regulations and a different body for the regulatory procedures.
Manufacturers' approval for commercializing product commercializing into the market. Due to this, in the North America region, stringent regulatory policies are expected to hinder the development of the cancer diagnostic market.
The regulatory requirement for approvals of marketing or CE certification and application of laws and regulations could lead to making major changes in business or paying penalties, including the potential loss of business licenses. The resources and costs required to comply with these laws, rules, and regulations are quite high. Different manufacturing challenges for lipid nanoparticle production
Post-COVID-19 Impact on the North America Melanoma Cancer Diagnostics Market
COVID-19 has positively affected the market. As the demand for diagnostics increased, preventive health check-ups were in high demand. Thus COVID-19 affected the melanoma cancer diagnostics market positively.
Recent Development
- In October 2022, Quest Diagnostics Incorporated announced that the company has collaborated with Decode health to get biomarker-based data that can help reduce the time and cost of developing novel diagnostic tests and drug targets for different types of cancer. This will help the company to find innovative paths in the field of R&D and increases the North America presence of the company in the market
- In May 2022, Myriad Genetics, Inc. announced the expansion of its strategic partnership with Intermountain Precision Genomics, a service of Intermountain Healthcare, to add a new liquid biopsy therapy selection test to the company's growing oncology portfolio. This results in growing liquid biopsy space for the precise tumor test
North America Melanoma Cancer Diagnostics Market Scope
The North America melanoma cancer diagnostics market is segmented into product type, test type, end user, and distribution channel. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to make strategic decisions to identify core market applications.
Product Type
- Instruments
- Consumables & Accessories
- Others
On the basis of type, the North America melanoma cancer diagnostics market is segmented into instruments, consumables & accessories, and others.
Test Type
- Biopsy
- Imaging test
- Immunohistochemical (IHC) tests
- Biomarkers test
- Fluorescent In Situ Hybridization (FISH) tests
- Comparative Genomic Hybridization (CGH) tests
- Others
Based on test type, the North America melanoma cancer diagnostics market is segmented into biomarkers test, imaging test, biopsy, Fluorescent In Situ Hybridization (FISH) tests, Comparative Genomic Hybridization (CGH) tests, Immunohistochemical (IHC) tests, and others.
End User
- Hospitals
- Associated labs
- Independent diagnostic laboratories
- Diagnostic imaging centers
- Cancer research institutes
- Others
Based on end user, the North America melanoma cancer diagnostics market is segmented into hospitals, associated labs, independent diagnostic laboratories, diagnostic imaging centers, cancer research institutes, and others.
Distribution Channel
- Direct Tender
- Retail Sales
- Others
Based on the distribution channel, the North America melanoma cancer diagnostics market is segmented into direct tender, retail sales, and others.
Melanoma Cancer Diagnostics Market Regional Analysis/Insights
The North America melanoma cancer market is analysed, and market size insights and trends are provided by product type, test type, end user, and distribution channel.
North America melanoma cancer market comprise of the countries the U.S., Canada, and Mexico.
The U.S. is expected to dominate the North America melanoma cancer diagnostics market due to growing demand for quality healthcare and rising demand for non-invasive testing methods.
The country section of the report also provides individual market-impacting factors and changes in regulations in the market that impact the current and future trends of the market. Data points, such as new and replacement sales, country demographics, disease epidemiology, and import-export tariffs, are some of the major pointers used to forecast the market scenario for individual countries. In addition, the presence and availability of North America brands and their challenges faced due to high competition from local and domestic brands and the impact of sales channels are considered while providing forecast analysis of the country data.
Competitive Landscape and Melanoma Cancer Diagnostics Market Share Analysis
北米の黒色腫がん診断市場の競争状況は、競合他社による詳細を提供します。含まれる詳細には、会社概要、会社の財務状況、収益、市場の可能性、研究開発への投資、新しい市場への取り組み、北米でのプレゼンス、生産拠点と施設、生産能力、会社の強みと弱み、製品の発売、製品の幅と広さ、アプリケーションの優位性などがあります。提供されている上記のデータ ポイントは、北米の黒色腫がん診断市場における会社の焦点にのみ関連しています。
北米の黒色腫癌診断市場で活動している主要企業には、Nanostring、Thermo Fisher Scientific Inc.、Quest Diagnostics Incorporated、Agilent Technologies, Inc、QIAGEN、Inivata Ltd、F. Hoffman-La Roche Ltd、Abbott、AMLo Biosciences Limited、Myriad genetics Genetics Inc、Castle Biosciences、DermTech、Michael Diagnostics Ltd、Damae Medical、Skin Analytics、DermLite、DermaSensor、Skyline Dx、Neracare GmbH、VERISKIN INC.、Illumina Inc、bioMerieux SA などがあります。
SKU-
世界初のマーケットインテリジェンスクラウドに関するレポートにオンラインでアクセスする
- インタラクティブなデータ分析ダッシュボード
- 成長の可能性が高い機会のための企業分析ダッシュボード
- カスタマイズとクエリのためのリサーチアナリストアクセス
- インタラクティブなダッシュボードによる競合分析
- 最新ニュース、更新情報、トレンド分析
- 包括的な競合追跡のためのベンチマーク分析のパワーを活用
目次
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE NORTH AMERICA MELANOMA CANCER DIAGNOSTICS MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 PRODUCT TYPE LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET END USER COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL'S MODEL
4.2 PORTER'S FIVE FORCES MODEL
5 EPIDEMIOLOGY
6 INDUSTRY INSIGHTS
6.1 DEMOGRAPHIC TRENDS
6.2 KEY PRICING STRATEGIES
6.2.1 PRODUCT INNOVATION
6.2.2 CONSUMER AWARNESS
6.2.3 A VAST NETWORK OF DISTRIBUTION
6.2.4 PARTNERSHIP WITH POPULAR BRANDS BY MAJOR PLAYERS
6.2.5 OTHERS
6.3 KEY PATIENT ENROLLMENT STRATEGIES
6.3.1 IDENTIFICATION OF CUSTOMERS NEED FOR INNOVATIVE DIAGOSTIC PRODUCTS
6.3.2 INCREASING SPECIFIC TACTICS FOR EVERY STEP
6.3.3 EDUCATE AND COMMUNICATE
6.3.4 IMPROVING DIAGNOSIS SEEKING RATE
6.4 INTERVIEWS WITH MANUFACTURING COMPANIES
7 MARKET OVERVIEW
7.1 DRIVERS
7.1.1 GROWING PREVALENCE OF MELANOMA CANCER
7.1.2 RISING PREFERENCE FOR PREVENTIVE HEALTH CHECK-UPS
7.1.3 NOVEL TECHNOLOGIES IN MELANOMA CANCER DIAGNOSTICS
7.1.4 INCREASING AWARENESS REGARDING MELANOMA CANCER
7.2 RESTRAINTS
7.2.1 LACK OF SKILLED AND CERTIFIED PROFESSIONALS
7.2.2 HIGH COST OF DIAGNOSTICS PROCEDURE FOR MELANOMA CANCERS
7.3 OPPORTUNITIES
7.3.1 INCREASING HEALTHCARE EXPENDITURE FOR MELANOMA CANCER TREATMENT
7.3.2 GOVERNMENT INITIATIVES TOWARD MELANOMA CANCER DIAGNOSTICS
7.3.3 INCREASED DEMAND FOR NON-INVASIVE TESTING METHODS
7.3.4 GROWING DEMAND FOR BETTER QUALITY HEALTHCARE
7.4 CHALLENGES
7.4.1 STRICT REGULATIONS AND STANDARDS FOR THE APPROVAL AND COMMERCIALIZATION OF MELANOMA CANCER DIAGNOSTIC PRODUCTS
7.4.2 RADIATION RISKS FROM IMAGING TESTS
8 NORTH AMERICA MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE
8.1 OVERVIEW
8.2 INSTRUMENTS
8.2.1 IMAGING INSTRUMENTS
8.2.1.1 ULTRASOUND SYSTEMS
8.2.1.2 MRI SYSTEMS
8.2.1.3 CT SYSTEMS
8.2.1.4 OTHERS
8.2.2 BIOPSY INSTRUMENTS
8.2.3 PATHOLOGY-BASED INSTRUMENTS
8.2.3.1 PCR INSTRUMENTS
8.2.3.2 CELL PROCESSORS
8.2.3.3 SLIDE STAINING SYSTEMS
8.2.3.4 TISSUE PROCESSING SYSTEMS
8.2.3.5 OTHER PATHOLOGY-BASED INSTRUMENTS
8.3 CONSUMABLES & ACCESSORIES
8.3.1 KITS
8.3.1.1 PCR KITS
8.3.1.2 NUCLEIC ACID ISOLATION KITS
8.3.1.3 DNA POLYMERASE KITS
8.3.1.4 OTHERS
8.3.2 PROBES
8.3.2.1 Q FISH
8.3.2.2 FLOW FISH
8.3.2.3 OTHERS
8.3.3 REAGENTS
8.3.3.1 ASSAYS
8.3.3.2 BUFFERS
8.3.3.3 PRIMERS
8.3.3.4 OTHERS
8.3.4 OTHER CONSUMABLES
8.4 OTHERS
9 NORTH AMERICA MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE
9.1 OVERVIEW
9.2 IMAGING TEST
9.2.1 ULTRASOUND
9.2.2 MRI
9.2.3 CHEST X-RAY
9.2.4 LYMPHOSCINTIGRAPHY
9.2.5 COMPUTED TOMOGRAPHY (CT) SCAN
9.2.6 POSITRON EMISSION TOMOGRAPHY (PET) SCAN
9.2.7 OTHERS
9.3 BIOPSY
9.3.1 OPTICAL BIOPSY
9.3.2 EXCISIONAL BIOPSY
9.3.3 INCISIONAL BIOPSY
9.3.4 SHAVE BIOPSY
9.3.5 PUNCH BIOPSY
9.3.6 OTHERS
9.4 IMMUNOHISTOCHEMICAL (IHC) TESTS
9.4.1 S100 PROTEIN FAMILY BIOPSY
9.4.2 MELAN-A
9.4.3 PMEL/PMEL17/SILV/GP100
9.4.4 TYROSINASE
9.4.5 MITF
9.4.6 SM5-1
9.4.7 CSPG4/HMW-MAA
9.5 BIOMARKER TEST
9.5.1 BRAF MUTATION TEST
9.5.2 NRAS MUTATION TEST
9.5.3 CKIT TEST
9.5.4 OTHERS
9.6 FLUORESCENT IN SITU HYBRIDIZATION (FISH) TESTS
9.7 COMPARATIVE GENOMIC HYBRIDIZATION (CGH) TESTS
9.8 OTHERS
10 NORTH AMERICA MELANOMA CANCER DIAGNOSTICS MARKET, BY END USER
10.1 OVERVIEW
10.2 HOSPITALS
10.3 ASSOCIATED LABS
10.4 DIAGNOSTIC IMAGING CENTERS
10.5 INDEPENDENT DIAGNOSTIC LABORATORIES
10.6 CANCER RESEARCH INSTITUTES
10.7 OTHERS
11 NORTH AMERICA MELANOMA CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL
11.1 OVERVIEW
11.2 DIRECT TENDER
11.3 RETAIL SALES
12 NORTH AMERICA MELANOMA CANCER DIAGNOSTICS MARKET, BY REGION
12.1 NORTH AMERICA
12.1.1 U.S.
12.1.2 CANADA
12.1.3 MEXICO
13 NORTH AMERICA MELANOMA CANCER DIAGNOSTICS MARKET, COMPANY LANDSCAPE
13.1 COMPANY SHARE ANALYSIS: NORTH AMERICA
14 SWOT ANALYSIS
15 COMPANY PROFILE
15.1 ABBOTT
15.1.1 COMPANY SNAPSHOT
15.1.2 REVENUE ANALYSIS
15.1.3 COMPANY SHARE ANALYSIS
15.1.4 PRODUCT PORTFOLIO
15.1.5 RECENT DEVELOPMENTS
15.2 ILLUMINA, INC.
15.2.1 COMPANY SNAPSHOT
15.2.2 REVENUE ANALYSIS
15.2.3 COMPANY SHARE ANALYSIS
15.2.4 PRODUCT PORTFOLIO
15.2.5 RECENT DEVELOPMENT
15.3 BIOMÉRIEUX SA
15.3.1 COMPANY SNAPSHOT
15.3.2 REVENUE ANALYSIS
15.3.3 COMPANY SHARE ANALYSIS
15.3.4 PRODUCT PORTFOLIO
15.3.5 RECENT DEVELOPMENTS
15.4 THERMO FISHER SCIENTIFIC INC.
15.4.1 COMPANY SNAPSHOT
15.4.2 REVENUE ANALYSIS
15.4.3 COMPANY SHARE ANALYSIS
15.4.4 PRODUCT PORTFOLIO
15.4.5 RECENT DEVELOPMENT
15.5 F. HOFFMANN-LA ROCHE LTD.
15.5.1 COMPANY SNAPSHOT
15.5.2 REVENUE ANALYSIS
15.5.3 COMPANY SHARE ANALYSIS
15.5.4 PRODUCT PORTFOLIO
15.5.5 RECENT DEVELOPMENT
15.6 AGILENT TECHNOLOGIES, INC.
15.6.1 COMPANY PROFILE
15.6.2 REVENUE ANALYSIS
15.6.3 PRODUCT PORTFOLIO
15.6.4 RECENT DEVELOPMENT
15.7 AMLO BIOSCIENCES LIMITED
15.7.1 COMPANY PROFILE
15.7.2 PRODUCT PORTFOLIO
15.7.3 RECENT DEVELOPMENT
15.8 CASTLE BIOSCIENCES INC
15.8.1 COMPANY SNAPSHOT
15.8.2 REVENUE ANALYSIS
15.8.3 PRODUCT PORTFOLIO
15.8.4 RECENT DEVELOPMENT
15.9 DAMAE MEDICAL
15.9.1 COMPANY PROFILE
15.9.2 PRODUCT PORTFOLIO
15.9.3 RECENT DEVELOPMENT
15.1 DERMLITE.
15.10.1 COMPANY PROFILE
15.10.2 PRODUCT PORTFOLIO
15.10.3 RECENT DEVELOPMENTS
15.11 DERMASENSOR
15.11.1 COMPANY PROFILE
15.11.2 PRODUCT PORTFOLIO
15.11.3 RECENT DEVELOPMENT
15.12 DERMTECH
15.12.1 COMPANY SNAPSHOT
15.12.2 REVENUE ANALYSIS
15.12.3 PRODUCT PORTFOLIO
15.12.4 RECENT DEVELOPMENT
15.13 INIVATA LTD.
15.13.1 COMPANY PROFILE
15.13.2 PRODUCT PORTFOLIO
15.13.3 RECENT DEVELOPMENT
15.14 MICHAEL DIAGNOSTICS LTD
15.14.1 COMPANY SNAPSHOT
15.14.2 PRODUCT PORTFOLIO
15.14.3 RECENT DEVELOPMENT
15.15 MYRIAD GENETICS, INC.
15.15.1 COMPANY SNAPSHOT
15.15.2 REVENUE ANALYSIS
15.15.3 PRODUCT PORTFOLIO
15.15.4 RECENT DEVELOPMENT
15.16 NANOSTRING
15.16.1 COMPANY SNAPSHOT
15.16.2 REVENUE ANALYSIS
15.16.3 PRODUCT PORTFOLIO
15.16.4 RECENT DEVELOPMENT
15.17 NERACARE GMBH
15.17.1 COMPANY PROFILE
15.17.2 PRODUCT PORTFOLIO
15.17.3 RECENT DEVELOPMENT
15.18 SKIN ANALYTICS
15.18.1 COMPANY PROFILE
15.18.2 PRODUCT PORTFOLIO
15.18.3 RECENT DEVELOPMENT
15.19 SKYLINEDX
15.19.1 COMPANY PROFILE
15.19.2 PRODUCT PORTFOLIO
15.19.3 RECENT DEVELOPMENTS
15.2 VERISKIN INC.
15.20.1 COMPANY PROFILE
15.20.2 PRODUCT PORTFOLIO
15.20.3 RECENT DEVELOPMENTS
15.21 QIAGEN
15.21.1 COMPANY SNAPSHOT
15.21.2 REVENUE ANALYSIS
15.21.3 PRODUCT PORTFOLIO
15.21.4 RECENT DEVELOPMENT
15.22 QUEST DIAGNOSTICS INCORPORATED (2022)
15.22.1 COMPANY SNAPSHOT
15.22.2 REVENUE ANALYSIS
15.22.3 PRODUCT PORTFOLIO
15.22.4 RECENT DEVELOPMENTS
16 QUESTIONNAIRE
17 RELATED REPORTS
表のリスト
TABLE 1 NORTH AMERICA MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 2 NORTH AMERICA INSTRUMENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 3 NORTH AMERICA INSTRUMENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 4 NORTH AMERICA IMAGING INSTRUMENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 5 NORTH AMERICA PATHOLOGY-BASED INSTRUMENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 6 NORTH AMERICA CONSUMERS & ACCESSORIES IN MELANOMA CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 7 NORTH AMERICA CONSUMABLES & ACCESSORIES IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 8 NORTH AMERICA KITS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 9 NORTH AMERICA PROBES IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 10 NORTH AMERICA REAGENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 11 NORTH AMERICA OTHERS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 12 NORTH AMERICA MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 13 NORTH AMERICA IMAGING TEST IN MELANOMA CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 14 NORTH AMERICA IMAGING TEST IN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 15 NORTH AMERICA BIOPSY IN MELANOMA CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 16 NORTH AMERICA BIOPSY IN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 17 NORTH AMERICA IMMUNOHISTOCHEMICAL (IHC) TESTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 18 NORTH AMERICA IMMUNOHISTOCHEMICAL (IHC) TESTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 19 NORTH AMERICA BIOMARKERS TEST IN MELANOMA CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 20 NORTH AMERICA BIOMARKERS TEST IN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 21 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) TESTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 22 NORTH AMERICA COMPARATIVE GENOMIC HYBRIDIZATION (CGH) TESTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 23 NORTH AMERICA OTHERS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 24 NORTH AMERICA MELANOMA CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 25 NORTH AMERICA HOSPITALS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 26 NORTH AMERICA ASSOCIATED LABS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 27 NORTH AMERICA DIAGNOSTIC IMAGING CENTERS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 28 NORTH AMERICA INDEPENDENT DIAGNOSTIC LABORATORIES IN MELANOMA CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 29 NORTH AMERICA CANCER RESEARCH INSTITUTES IN MELANOMA CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 30 NORTH AMERICA OTHERS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 31 NORTH AMERICA MELANOMA CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 32 NORTH AMERICA DIRECT TENDER IN MELANOMA CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 33 NORTH AMERICA RETAIL SALES IN MELANOMA CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 34 NORTH AMERICA MELANOMA CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2021-2030 (USD MILLION)
TABLE 35 NORTH AMERICA MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 36 NORTH AMERICA INSTRUMENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 37 NORTH AMERICA PATHOLOGY-BASED INSTRUMENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 38 NORTH AMERICA IMAGING INSTRUMENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 39 NORTH AMERICA CONSUMABLES & ACCESSORIES IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 40 NORTH AMERICA KITS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 41 NORTH AMERICA REAGENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 42 NORTH AMERICA PROBES IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 43 NORTH AMERICA MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 44 NORTH AMERICA BIOMARKERS TEST IN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 45 NORTH AMERICA IMAGING TEST IN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 46 NORTH AMERICA BIOPSY IN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 47 NORTH AMERICA IMMUNOHISTOCHEMICAL (IHC) TESTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 48 NORTH AMERICA MELANOMA CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 49 NORTH AMERICA MELANOMA CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 50 U.S. MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 51 U.S. INSTRUMENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 52 U.S. PATHOLOGY-BASED INSTRUMENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 53 U.S. IMAGING INSTRUMENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 54 U.S. CONSUMABLES & ACCESSORIES IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 55 U.S. KITS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 56 U.S. REAGENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 57 U.S. PROBES IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 58 U.S. MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 59 U.S. BIOMARKERS TEST IN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 60 U.S. IMAGING TEST IN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 61 U.S. BIOPSY IN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 62 U.S. IMMUNOHISTOCHEMICAL (IHC) TESTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 63 U.S. MELANOMA CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 64 U.S. MELANOMA CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 65 CANADA MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 66 CANADA INSTRUMENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 67 CANADA PATHOLOGY-BASED INSTRUMENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 68 CANADA IMAGING INSTRUMENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 69 CANADA CONSUMABLES & ACCESSORIES IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 70 CANADA KITS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 71 CANADA REAGENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 72 CANADA PROBES IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 73 CANADA MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 74 CANADA BIOMARKERS TEST IN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 75 CANADA IMAGING TEST IN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 76 CANADA BIOPSY IN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 77 CANADA IMMUNOHISTOCHEMICAL (IHC) TESTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 78 CANADA MELANOMA CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 79 CANADA MELANOMA CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 80 MEXICO MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 81 MEXICO INSTRUMENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 82 MEXICO PATHOLOGY-BASED INSTRUMENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 83 MEXICO IMAGING INSTRUMENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 84 MEXICO CONSUMABLES & ACCESSORIES IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 85 MEXICO KITS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 86 MEXICO REAGENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 87 MEXICO PROBES IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 88 MEXICO MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 89 MEXICO BIOMARKERS TEST IN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 90 MEXICO IMAGING TEST IN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 91 MEXICO BIOPSY IN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 92 MEXICO IMMUNOHISTOCHEMICAL (IHC) TESTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 93 MEXICO MELANOMA CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 94 MEXICO MELANOMA CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
図表一覧
FIGURE 1 NORTH AMERICA MELANOMA CANCER DIAGNOSTICS MARKET: SEGMENTATION
FIGURE 2 NORTH AMERICA MELANOMA CANCER DIAGNOSTICS MARKET: DATA TRIANGULATION
FIGURE 3 NORTH AMERICA MELANOMA CANCER DIAGNOSTICS MARKET: DROC ANALYSIS
FIGURE 4 NORTH AMERICA MELANOMA CANCER DIAGNOSTICS MARKET: NORTH AMERICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 NORTH AMERICA MELANOMA CANCER DIAGNOSTICS MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 NORTH AMERICA MELANOMA CANCER DIAGNOSTICS MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 NORTH AMERICA MELANOMA CANCER DIAGNOSTICS MARKET: DBMR MARKET POSITION GRID
FIGURE 8 NORTH AMERICA MELANOMA CANCER DIAGNOSTICS MARKET: MARKET END USER COVERAGE GRID
FIGURE 9 NORTH AMERICA MELANOMA CANCER DIAGNOSTICS MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 NORTH AMERICA MELANOMA CANCER DIAGNOSTICS MARKET: SEGMENTATION
FIGURE 11 THE GROWING PREVALENCE OF MELANOMA CANCER AND THE INCREASING AWARENESS REGARDING MELANOMA CANCER ARE EXPECTED TO DRIVE THE NORTH AMERICA MELANOMA CANCER DIAGNOSTICS MARKET GROWTH IN THE FORECAST PERIOD OF 2023 TO 2030
FIGURE 12 INSTRUMENTS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA MELANOMA CANCER DIAGNOSTICS MARKET IN 2023 & 2030
FIGURE 13 ESTIMATED PREVALENCE OF MELANOMA CANCER IN 2020
FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE NORTH AMERICA MELANOMA CANCER DIAGNOSTICS MARKET
FIGURE 15 NUMBER OF NEW CASES IN 2018 IN FEMALES OF ALL AGES
FIGURE 16 AGEING EUROPE POPULATION (IN MILLION)
FIGURE 17 ESTIMATED LIFETIME CARE SPENDING
FIGURE 18 NORTH AMERICA MELANOMA CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE, 2022
FIGURE 19 NORTH AMERICA MELANOMA CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE, 2023-2030 (USD MILLION)
FIGURE 20 NORTH AMERICA MELANOMA CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE, CAGR (2023-2030)
FIGURE 21 NORTH AMERICA MELANOMA CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE, LIFELINE CURVE
FIGURE 22 NORTH AMERICA MELANOMA CANCER DIAGNOSTICS MARKET: BY TEST TYPE, 2022
FIGURE 23 NORTH AMERICA MELANOMA CANCER DIAGNOSTICS MARKET: BY TEST TYPE, 2023-2030 (USD MILLION)
FIGURE 24 NORTH AMERICA MELANOMA CANCER DIAGNOSTICS MARKET: BY TEST TYPE, CAGR (2023-2030)
FIGURE 25 NORTH AMERICA MELANOMA CANCER DIAGNOSTICS MARKET: BY TEST TYPE, LIFELINE CURVE
FIGURE 26 NORTH AMERICA MELANOMA CANCER DIAGNOSTICS MARKET: BY END USER, 2022
FIGURE 27 NORTH AMERICA MELANOMA CANCER DIAGNOSTICS MARKET: BY END USER, 2023-2030 (USD MILLION)
FIGURE 28 NORTH AMERICA MELANOMA CANCER DIAGNOSTICS MARKET: BY END USER, CAGR (2023-2030)
FIGURE 29 NORTH AMERICA MELANOMA CANCER DIAGNOSTICS MARKET: BY END USER, LIFELINE CURVE
FIGURE 30 NORTH AMERICA MELANOMA CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, 2022
FIGURE 31 NORTH AMERICA MELANOMA CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION)
FIGURE 32 NORTH AMERICA MELANOMA CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030)
FIGURE 33 NORTH AMERICA MELANOMA CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 34 NORTH AMERICA MELANOMA CANCER DIAGNOSTICS MARKET: SNAPSHOT (2022)
FIGURE 35 NORTH AMERICA MELANOMA CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022)
FIGURE 36 NORTH AMERICA MELANOMA CANCER DIAGNOSTICS MARKET: BY COUNTRY (2023 & 2030)
FIGURE 37 NORTH AMERICA MELANOMA CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022 & 2030)
FIGURE 38 NORTH AMERICA MELANOMA CANCER DIAGNOSTICS MARKET: PRODUCT TYPE (2023-2030)
FIGURE 39 NORTH AMERICA MELANOMA CANCER DIAGNOSTICS MARKET: COMPANY SHARE 2022 (%)
調査方法
データ収集と基準年分析は、大規模なサンプル サイズのデータ収集モジュールを使用して行われます。この段階では、さまざまなソースと戦略を通じて市場情報または関連データを取得します。過去に取得したすべてのデータを事前に調査および計画することも含まれます。また、さまざまな情報ソース間で見られる情報の不一致の調査も含まれます。市場データは、市場統計モデルと一貫性モデルを使用して分析および推定されます。また、市場シェア分析と主要トレンド分析は、市場レポートの主要な成功要因です。詳細については、アナリストへの電話をリクエストするか、お問い合わせをドロップダウンしてください。
DBMR 調査チームが使用する主要な調査方法は、データ マイニング、データ変数が市場に与える影響の分析、および一次 (業界の専門家) 検証を含むデータ三角測量です。データ モデルには、ベンダー ポジショニング グリッド、市場タイムライン分析、市場概要とガイド、企業ポジショニング グリッド、特許分析、価格分析、企業市場シェア分析、測定基準、グローバルと地域、ベンダー シェア分析が含まれます。調査方法について詳しくは、お問い合わせフォームから当社の業界専門家にご相談ください。
カスタマイズ可能
Data Bridge Market Research は、高度な形成的調査のリーダーです。当社は、既存および新規のお客様に、お客様の目標に合致し、それに適したデータと分析を提供することに誇りを持っています。レポートは、対象ブランドの価格動向分析、追加国の市場理解 (国のリストをお問い合わせください)、臨床試験結果データ、文献レビュー、リファービッシュ市場および製品ベース分析を含めるようにカスタマイズできます。対象競合他社の市場分析は、技術ベースの分析から市場ポートフォリオ戦略まで分析できます。必要な競合他社のデータを、必要な形式とデータ スタイルでいくつでも追加できます。当社のアナリスト チームは、粗い生の Excel ファイル ピボット テーブル (ファクト ブック) でデータを提供したり、レポートで利用可能なデータ セットからプレゼンテーションを作成するお手伝いをしたりすることもできます。
